Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
L
141080
vs
K
KOSPI 200
Over the past 12 months, LigaChem Biosciences Inc has underperformed KOSPI 200, delivering a return of -45% compared to KOSPI 200's +125% growth.
Stocks Performance
141080 vs KOSPI 200
Performance Gap
141080 vs KOSPI 200
Performance By Year
141080 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
LigaChem Biosciences Inc
Glance View
LegoChem Biosciences is a South Korean drug developer best known for building cancer medicines, especially antibody-drug conjugates, or ADCs. An ADC links a cancer-targeting antibody to a powerful drug so the medicine can attack tumors more precisely than traditional chemotherapy. The company also works on small-molecule drugs and the chemistry behind them, but its core role is turning early research into drug candidates that can move forward in development. Its main customers are not retail buyers. Instead, the company works with pharmaceutical companies and biotech partners that license its drug candidates or its drug-conjugation technology. LegoChem Biosciences makes money through research collaboration payments, license fees, milestone payments tied to development progress, and royalties if partnered drugs reach the market. If it commercializes any products itself, it would also earn drug sales revenue, but partnerships are central to the business model. What makes the company different is that it sits in the middle of the drug-development chain: it creates the chemistry and early drug assets, then often hands them to bigger partners with the resources to run later-stage trials and commercialization. That gives it a platform-like role in oncology drug discovery, where the value comes from its scientific know-how, patent portfolio, and ability to design linkers, payloads, and other building blocks used in ADC medicines.